Every 8-K that PHARM-BIO SERV INC (PBSV) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PBSV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PBSV filings page.
Pharma-Bio Serv, Inc. (PBSV) reported higher revenue and improved profitability for the quarter and nine months ended July 31, 2026. Revenue was approximately $2.3 million for the quarter and $7.3 million for the nine-month period, up about $0.4 million and $0.5 million, respectively, from the same periods a year earlier.
For the quarter, the company recorded a small net loss of $14 thousand, while for the nine months it generated net income of approximately $252 thousand, representing improvements of about $190 thousand and $352 thousand versus the prior-year periods. Chief Executive Officer Victor Sanchez stated that the results reflect strong client relationships, the company’s specialized regulatory and compliance capabilities, and ongoing efforts to focus on markets where its expertise provides a competitive advantage and to drive operating efficiencies.
Pharma-Bio Serv, Inc. reported higher revenue and profit for the quarter ended April 30, 2026. Revenue for the three and six months was approximately $2.7 million and $5.0 million, up about $0.3 million and $0.1 million from the same periods last year.
Net income for the three and six months reached approximately $0.2 million and $0.3 million, increases of about $0.1 million and $0.2 million year over year. Management highlighted stronger profitability driven by focusing on higher-opportunity markets and maintaining disciplined cost control and operational efficiency.
Pharma-Bio Serv, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Stockholders elected Irving Wiesen as a Class I director to serve until the 2029 Annual Meeting, with 10,208,071 votes for and 195,625 votes withheld, plus 2,839,645 broker non-votes. Stockholders also ratified the selection of Crowe PR PSC as independent certified public accountants for the fiscal year ending October 31, 2026, with 13,241,794 votes for, 3 against and 1,544 abstentions.
Pharma-Bio Serv reported revenues of approximately $2.3 million for the quarter ended January 31, 2026, a decrease of about $0.2 million from the same period last year. Despite lower sales, the company posted net income of $32,860, an improvement of $24,324 compared with a slight loss a year earlier.
Management highlighted ongoing efforts to sharpen the service portfolio, reinforce operational alignment, and focus on markets where its consulting capabilities add the most value. The CEO stated that improved operational efficiency supported the return to profit and expressed confidence in building momentum through stronger client relationships and disciplined cost management.
Pharma-Bio Serv, Inc. reported that it has released its financial results for the year ended October 31, 2025. The company announced these full-year results through a press release dated January 29, 2026, which is attached to this report as Exhibit 99.1.
The filing emphasizes that the press release and related financial information are being furnished rather than filed, meaning they are not automatically incorporated into other securities filings unless specifically referenced.
Pharma-Bio Serv, Inc. filed a current report to disclose that it issued a press release announcing its results of operations for the three and nine months ended July 31, 2025. The press release is furnished as Exhibit 99.1 to the report, providing the detailed financial and operating results for that period. The company clarifies that this information, including Exhibit 99.1, is furnished rather than filed, meaning it is not subject to certain liability provisions under the Exchange Act or automatically incorporated into other securities filings. The report is signed on behalf of the company by Pedro J. Lasanta, its Chief Financial Officer, Vice President Finance and Administration, and Secretary.